SCHEMBL25363542

SCHEMBL25363542

O=C(O)[C@@H]1C[C@@H](C2CCCC2)CN1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
ALOX15 P16050 1/20 0.52
CYP2C19 P33261 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
DPP4 P27487 1/20 0.48
GRIK1 P39086 4/20 0.44
GRIA1 P42261 3/20 0.44
GRIA2 P42262 3/20 0.44
GRIA3 P42263 3/20 0.44
GRIA4 P48058 3/20 0.44
GRIK2 Q13002 1/20 0.44
GRIK3 Q13003 1/20 0.44
GRIK4 Q16099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25364958 1.00 CYP1A2 (0.52) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL24113373 1.00 CYP1A2 (0.52) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL2238814 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL7873502 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL29035113 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL7876588 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
Hydrochloric Acid SCHEMBL25365192 0.98 CYP1A2 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL197230 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL7876596 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL197231 0.98 DPP4 (0.50) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed